ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Single-Center’s Outcomes of Combined Heart-Liver Transplantation

R. W. Lincoln1, K. Kalvakuri2, A. Guha2, A. Bhimaraj2, E. E. Suarez2, A. Saharia3, C. M. Mobley3, F. Amirkhosravi3, J. Krisl1

1Pharmacy, Houston Methodist Hospital, Houston, TX, 2DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, 3Surgery, Houston Methodist Hospital, Houston, TX

Meeting: 2022 American Transplant Congress

Abstract number: 1115

Keywords: Immunosuppression, Induction therapy, Infection, Rejection

Topic: Clinical Science » Heart » 63 - Heart and VADs: All Topics

Session Information

Session Name: Heart and VADs: All Topics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.

*Methods: This is a retrospective, single-centered, observational study evaluating the 6-month outcomes of CHLT. All CHLT from January 2017-May 2021 were included for analysis. The primary outcome of this study was incidence of cardiac allograft rejection within 6 months post-transplant. Protocol endomyocardial biopsies are performed at weeks 1, 2, 3, 4, 6, 8, 10, 12, and months 4, 5, and 6 post-transplant. Secondary outcomes include changes in left ventricular ejection fraction (LVEF), liver enzymes, and donor specific antibody (DSA) development. Surveillance for DSA is performed per protocol based on patient’s sensitization pre-transplant. Other outcomes include mortality and infections within 1 year post-transplant.

*Results: From January 2017-May 2021, there were 218 protocol biopsies performed on 21 CHLT at our institution. At time of transplant, median age was 62 years old and 80.9% of patients were male. Amyloidosis was the most common reason for CHLT (47.6%). Seven (33.3%) patients were sensitized (peak cPRA >20% in either Class I or Class II DSA’s) prior to transplant; 19 (90.5%) patients did not receive induction, per institution protocol. At 6 months post-transplant, only 2 CHLT had cardiac allograft cellular rejection (2R or greater). Both rejections occurred within 2 weeks of transplant and were successfully treated with corticosteroids. There were no cases of AMR. Median LVEF at 6 months was 60-64%. Liver enzymes were stable after transplant and within the first 6 months after transplant. Four CHLT developed weak DSA’s post-transplant that cleared during subsequent monitoring. There were a total of 4 CMV viremia infections and 9 non-CMV infections within 1 year of transplant; median time to infections were 189 and 109 days after transplant, respectively. No CHLT patients expired at any point during the study follow-up period.

*Conclusions: Our center’s experience with CHLT show excellent outcomes with low rates of cardiac allograft rejection and low development of DSA’s within 6 months after transplant.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lincoln RW, Kalvakuri K, Guha A, Bhimaraj A, Suarez EE, Saharia A, Mobley CM, Amirkhosravi F, Krisl J. A Single-Center’s Outcomes of Combined Heart-Liver Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/a-single-centers-outcomes-of-combined-heart-liver-transplantation/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences